This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (2588)  • Contact me when this article is cited  Related Content  • Related letter  • Related articles  • Similar articles in JAMA  Topic Collections  • Nutritional and Metabolic Disorders  • Lipids and Lipid Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Results of AFCAPS/TexCAPS

John R. Downs, MD; Michael Clearfield, DO; Stephen Weis, DO; Edwin Whitney, MD; Deborah R. Shapiro, DrPH; Polly A. Beere, MD, PhD; Alexandra Langendorfer, MS; Evan A. Stein, MD; William Kruyer, MD; Antonio M. Gotto, Jr, MD, DPhil; for the AFCAPS/TexCAPS Research Group

JAMA. 1998;279:1615-1622.

Context.— Although cholesterol-reducing treatment has been shown to reduce fatal and nonfatal coronary disease in patients with coronary heart disease (CHD), it is unknown whether benefit from the reduction of low-density lipoprotein cholesterol (LDL-C) in patients without CHD extends to individuals with average serum cholesterol levels, women, and older persons.

Objective.— To compare lovastatin with placebo for prevention of the first acute major coronary event in men and women without clinically evident atherosclerotic cardiovascular disease with average total cholesterol (TC) and LDL-C levels and below-average high-density lipoprotein cholesterol (HDL-C) levels.

Design.— A randomized, double-blind, placebo-controlled trial.

Setting.— Outpatient clinics in Texas.

Participants.— A total of 5608 men and 997 women with average TC and LDL-C and below-average HDL-C (as characterized by lipid percentiles for an age- and sex-matched cohort without cardiovascular disease from the National Health and Nutrition Examination Survey [NHANES] III). Mean (SD) TC level was 5.71 (0.54) mmol/L (221 [21] mg/dL) (51st percentile), mean (SD) LDL-C level was 3.89 (0.43) mmol/L (150 [17] mg/dL) (60th percentile), mean (SD) HDL-C level was 0.94 (0.14) mmol/L (36 [5] mg/dL) for men and 1.03 (0.14) mmol/L (40 [5] mg/dL) for women (25th and 16th percentiles, respectively), and median (SD) triglyceride levels were 1.78 (0.86) mmol/L (158 [76] mg/dL) (63rd percentile).

Intervention.— Lovastatin (20-40 mg daily) or placebo in addition to a low–saturated fat, low-cholesterol diet.

Main Outcome Measures.— First acute major coronary event defined as fatal or nonfatal myocardial infarction, unstable angina, or sudden cardiac death.

Results.— After an average follow-up of 5.2 years, lovastatin reduced the incidence of first acute major coronary events (183 vs 116 first events; relative risk [RR], 0.63; 95% confidence interval [CI], 0.50-0.79; P<.001), myocardial infarction (95 vs 57 myocardial infarctions; RR, 0.60; 95% CI, 0.43-0.83; P=.002), unstable angina (87 vs 60 first unstable angina events; RR, 0.68; 95% CI, 0.49-0.95; P=.02), coronary revascularization procedures (157 vs 106 procedures; RR, 0.67; 95% CI, 0.52-0.85; P=.001), coronary events (215 vs 163 coronary events; RR, 0.75; 95% CI, 0.61-0.92; P=.006), and cardiovascular events (255 vs 194 cardiovascular events; RR, 0.75; 95% CI, 0.62-0.91; P=.003). Lovastatin (20-40 mg daily) reduced LDL-C by 25% to 2.96 mmol/L (115 mg/dL) and increased HDL-C by 6% to 1.02 mmol/L (39 mg/dL). There were no clinically relevant differences in safety parameters between treatment groups.

Conclusions.— Lovastatin reduces the risk for the first acute major coronary event in men and women with average TC and LDL-C levels and below-average HDL-C levels. These findings support the inclusion of HDL-C in risk-factor assessment, confirm the benefit of LDL-C reduction to a target goal, and suggest the need for reassessment of the National Cholesterol Education Program guidelines regarding pharmacological intervention.

From the Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, Tex (Dr Downs); University of North Texas Health Science Center, Fort Worth (Drs Clearfield and Weis); the Heart and Vascular Institute of Texas, San Antonio (Dr Whitney); Merck & Co Inc, West Point, Pa (Drs Shapiro and Beere and Ms Langendorfer); Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio (Dr Stein); Brooks Air Force Base, San Antonio (Dr Kruyer); and Cornell University Medical College, New York, NY (Dr Gotto).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED LETTER

The Role of Statins in Primary Prevention of Cardiovascular Disease
Klaus Eichler, Milo A. Puhan, and Lucas M. Bachmann
Arch Intern Med. 2007;167(10):1100.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Antiatherothrombotic Properties of Statins: Implications for Cardiovascular Event Reduction
Robert S. Rosenson and Christine C. Tangney
JAMA. 1998;279(20):1643-1650.
ABSTRACT | FULL TEXT  

Lipid-Lowering Therapy in Low-Risk Patients
Thomas A. Pearson
JAMA. 1998;279(20):1659-1661.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Associations Between Statin Treatment and Markers of Inflammation, Vasoconstriction, and Coagulation in Patients With Abdominal Aortic Aneurysm
Gottsater et al.
VASC ENDOVASCULAR SURG 2009;42:567-573.
ABSTRACT  

Novel and Conventional Biomarkers for Prediction of Incident Cardiovascular Events in the Community
Melander et al.
JAMA 2009;302:49-57.
ABSTRACT | FULL TEXT  

The Vytorin on Carotid Intima-Media Thickness and Overall Arterial Rigidity (VYCTOR) Study
Meaney et al.
J Clin Pharmacol 2009;49:838-847.
ABSTRACT | FULL TEXT  

Metabolic syndrome: intima-media thickness and beyond.
Golomb
J Am Coll Cardiol 2009;53:2280-2282.
FULL TEXT  

Red Yeast Rice for Dyslipidemia in Statin-Intolerant Patients: A Randomized Trial
Becker et al.
ANN INTERN MED 2009;150:830-839.
ABSTRACT | FULL TEXT  

Mendelian Randomization: Nature's Randomized Trial in the Post-Genome Era
Thanassoulis and O'Donnell
JAMA 2009;301:2386-2388.
FULL TEXT  

Late Clinical Events After Drug-Eluting Stents: The Interplay Between Stent-Related and Natural History-Driven Events
Leon et al.
J Am Coll Cardiol Intv 2009;2:504-512.
ABSTRACT | FULL TEXT  

Effects of Statins on the Pharmacokinetics of Midazolam in Healthy Volunteers
Kokudai et al.
J Clin Pharmacol 2009;49:568-573.
ABSTRACT | FULL TEXT  

Statin Adherence and Risk of Accidents: A Cautionary Tale
Dormuth et al.
Circulation 2009;119:2051-2057.
ABSTRACT | FULL TEXT  

Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease
Karalis
Mayo Clin Proc. 2009;84:345-352.
ABSTRACT | FULL TEXT  

Management of Hyperlipidemia in Older Adults
Alexander et al.
J CARDIOVASC PHARMACOL THER 2009;14:49-58.
ABSTRACT  

Carotid Intima-Media Thickness and Coronary Artery Calcium Score as Indications of Subclinical Atherosclerosis
Lester et al.
Mayo Clin Proc. 2009;84:229-233.
ABSTRACT | FULL TEXT  

Pravastatin for Cardiovascular Event Primary Prevention in Patients With Mild-to-Moderate Hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study
Kushiro et al.
Hypertension 2009;53:135-141.
ABSTRACT | FULL TEXT  

Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk.
Robinson et al.
J Am Coll Cardiol 2009;53:316-322.
ABSTRACT | FULL TEXT  

Association Between Statin Use and Risk for Keratinocyte Carcinoma in the Veterans Affairs Topical Tretinoin Chemoprevention Trial
Dore et al.
ANN INTERN MED 2009;150:9-18.
ABSTRACT | FULL TEXT  

JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean?
SHISHEHBOR and HAZEN
Cleveland Clinic Journal of Medicine 2009;76:37-44.
ABSTRACT | FULL TEXT  

Statins alter neutrophil migration by modulating cellular Rho activity--a potential mechanism for statins-mediated pleotropic effects?
Maher et al.
J. Leukoc. Biol. 2009;85:186-193.
ABSTRACT | FULL TEXT  

Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis: Insights From ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation)
Nicholls et al.
Circulation 2008;118:2506-2514.
ABSTRACT | FULL TEXT  

The Metabolic Syndrome
Cornier et al.
Endocr. Rev. 2008;29:777-822.
ABSTRACT | FULL TEXT  

Interaction between statins and clopidogrel: is there anything clinically relevant?
Bhindi et al.
QJM 2008;101:915-925.
ABSTRACT | FULL TEXT  

Primary Prevention and Statins: Is It Just About Going to Class?
Krasuski
Mayo Clin Proc. 2008;83:1313-1315.
FULL TEXT  

Comparison of Cardiovascular Event Rates in Patients Without Cardiovascular Disease in Whom Atorvastatin or Simvastatin Was Newly Initiated
Jacobson et al.
Mayo Clin Proc. 2008;83:1316-1325.
ABSTRACT | FULL TEXT  

Primary Prevention of Cardiovascular Mortality and Events With Statin Treatments A Network Meta-Analysis Involving More Than 65,000 Patients.
Mills et al.
J Am Coll Cardiol 2008;52:1769-1781.
ABSTRACT | FULL TEXT  

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker et al.
NEJM 2008;359:2195-2207.
ABSTRACT | FULL TEXT  

Statin Use Is Associated with Prolonged Survival of Renal Transplant Recipients
Wiesbauer et al.
J. Am. Soc. Nephrol. 2008;19:2211-2218.
ABSTRACT | FULL TEXT  

Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels
Hausenloy and Yellon
Postgrad. Med. J. 2008;84:590-598.
ABSTRACT | FULL TEXT  

Is Red Yeast Rice a Suitable Alternative for Statins?-Reply-I
Becker et al.
Mayo Clin Proc. 2008;83:1294-1296.
FULL TEXT  

Lipid-Lowering Therapy is Related to Inflammatory Markers and 3-Year Mortality in Patients With Critical Limb Ischemia
Isma et al.
ANGIOLOGY 2008;59:542-548.
ABSTRACT  

Metabolism, Pharmacokinetics, and Excretion of a Cholesteryl Ester Transfer Protein Inhibitor, Torcetrapib, in Rats, Monkeys, and Mice: Characterization of Unusual and Novel Metabolites by High-Resolution Liquid Chromatography-Tandem Mass Spectrometry and 1H Nuclear Magnetic Resonance
Prakash et al.
Drug Metab. Dispos. 2008;36:2064-2079.
ABSTRACT | FULL TEXT  

Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline
Rosenzweig et al.
J. Clin. Endocrinol. Metab. 2008;93:3671-3689.
ABSTRACT | FULL TEXT  

Statins, Low-Density Lipoprotein Cholesterol, and Risk of Cancer
Alsheikh-Ali et al.
J Am Coll Cardiol 2008;52:1141-1147.
ABSTRACT | FULL TEXT  

Targeted versus global approaches to the management of hypercholesterolaemia
Reynolds et al.
The Journal of the Royal Society for the Promotion of Health 2008;128:248-254.
ABSTRACT  

Evidence Mandating Earlier and More Aggressive Treatment of Hypercholesterolemia
Steinberg et al.
Circulation 2008;118:672-677.
FULL TEXT  

The Role of Statin Drugs in the Management of the Peripheral Vascular Patient
Samson
VASC ENDOVASCULAR SURG 2008;42:352-366.
ABSTRACT  

A Practical 'ABCDE' Approach to the Metabolic Syndrome
Blaha et al.
Mayo Clin Proc. 2008;83:932-943.
ABSTRACT | FULL TEXT  

Do People With Diabetes Need Statins?
White
The Diabetes Educator 2008;34:664-673.
ABSTRACT | FULL TEXT  

The Parodox of Glycemic Control and Cardiovascular Complications: Sorting Out the Data
Dokken
Diabetes Spectr. 2008;21:150-152.
FULL TEXT  

The Association of Testosterone Levels with Overall Sleep Quality, Sleep Architecture, and Sleep-Disordered Breathing
Barrett-Connor et al.
J. Clin. Endocrinol. Metab. 2008;93:2602-2609.
ABSTRACT | FULL TEXT  

Over-the-Counter Sales of Statins and Other Drugs for Asymptomatic Conditions
Tinetti
NEJM 2008;358:2728-2732.
FULL TEXT  

Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels
Hausenloy and Yellon
Heart 2008;94:706-714.
ABSTRACT | FULL TEXT  

Almonds Reduce Biomarkers of Lipid Peroxidation in Older Hyperlipidemic Subjects
Jenkins et al.
J. Nutr. 2008;138:908-913.
ABSTRACT | FULL TEXT  

Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes: The SANDS Randomized Trial
Howard et al.
JAMA 2008;299:1678-1689.
ABSTRACT | FULL TEXT  

Primary prevention with pravastatin for 5 years continued to prevent coronary events in the next 10 years
Woodend
Evid. Based Nurs. 2008;11:52-52.
FULL TEXT  

Letter Regarding Article by Leeper et al, "Statin Use in Patients With Extremely Low Low-Density Lipoprotein Levels Is Associated With Improved Survival"
Anderson and Salgado
Circulation 2008;117:e174-e174.
FULL TEXT  

Applications of statins in cardiothoracic surgery: more than just lipid-lowering
Paraskevas
Eur. J. Cardiothorac. Surg. 2008;33:377-390.
ABSTRACT | FULL TEXT  

HDL-cholesterol modulation and its impact on the management of cardiovascular risk
Ferns and Keti
Ann Clin Biochem 2008;45:122-128.
ABSTRACT | FULL TEXT  

Lifestyle or Life-Saving Medicines? A Primary Healthcare Professional and Consumer Opinion Survey on Over-the-Counter Statins
Vamvakopoulos et al.
The Annals of Pharmacotherapy 2008;42:413-420.
ABSTRACT | FULL TEXT  

Statin Therapy for Stroke Prevention
Nassief and Marsh
Stroke 2008;39:1042-1048.
ABSTRACT | FULL TEXT  

Lipid Management to Reduce Cardiovascular Risk: A New Strategy Is Required
Superko and King
Circulation 2008;117:560-568.
FULL TEXT  

Usefulness of Pravastatin in Primary Prevention of Cardiovascular Events in Women: Analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA Study)
Mizuno et al.
Circulation 2008;117:494-502.
ABSTRACT | FULL TEXT  

Fish-oil supplementation in patients with implantable cardioverter defibrillators: a meta-analysis
Jenkins et al.
CMAJ 2008;178:157-164.
ABSTRACT | FULL TEXT  

Adolescent Overweight and Future Adult Coronary Heart Disease
Bibbins-Domingo et al.
NEJM 2007;357:2371-2379.
ABSTRACT | FULL TEXT  

Family practice patients' adherence to statin medications
Natarajan et al.
cfp 2007;53:2144-2145.
ABSTRACT | FULL TEXT  

Impact of Statins on Risk of Stroke: A Meta-Analysis
Henyan et al.
The Annals of Pharmacotherapy 2007;41:1937-1945.
ABSTRACT | FULL TEXT  

Primary Prevention of Coronary Artery Disease
Domanski
NEJM 2007;357:1543-1545.
FULL TEXT  

Impact of C-reactive protein on treatment of patients with cardiovascular disease
Gortney and Sanders
Am J Health Syst Pharm 2007;64:2009-2016.
ABSTRACT | FULL TEXT  

Simvastatin Protects against Multiple Low-Dose Streptozotocin-Induced Type 1 Diabetes in CD-1 Mice and Recurrence of Disease in Nonobese Diabetic Mice
Rydgren et al.
J. Pharmacol. Exp. Ther. 2007;323:180-185.
ABSTRACT | FULL TEXT  

Preprocedural Statin Therapy in Percutaneous Coronary Intervention
Cahoon and Crouch
The Annals of Pharmacotherapy 2007;41:1687-1693.
ABSTRACT | FULL TEXT  

Discontinuation of Statin Therapy and Clinical Outcome After Ischemic Stroke
Colivicchi et al.
Stroke 2007;38:2652-2657.
ABSTRACT | FULL TEXT  

HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events
Barter et al.
NEJM 2007;357:1301-1310.
ABSTRACT | FULL TEXT  

Are patients with hyperlipidemia undertreated?: Study of patients admitted to hospital with coronary events
Lipson et al.
cfp 2007;53:1502-1507.
ABSTRACT | FULL TEXT  

High-Density Lipoprotein as a Therapeutic Target: A Systematic Review
Singh et al.
JAMA 2007;298:786-798.
ABSTRACT | FULL TEXT  

Statins and the Risk of Colorectal Cancer: A Meta-Analysis of 18 Studies Involving More Than 1.5 Million Patients
Bonovas et al.
JCO 2007;25:3462-3468.
ABSTRACT | FULL TEXT  

Statin-Induced Breast Cancer Cell Death: Role of Inducible Nitric Oxide and Arginase-Dependent Pathways
Kotamraju et al.
Cancer Res. 2007;67:7386-7394.
ABSTRACT | FULL TEXT  

Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer: Insights From Large Randomized Statin Trials
Alsheikh-Ali et al.
J Am Coll Cardiol 2007;50:409-418.
ABSTRACT | FULL TEXT  

The Unique Character of Cardiovascular Disease in Chronic Kidney Disease and Its Implications for Treatment with Lipid-Lowering Drugs
Nogueira and Weir
CJASN 2007;2:766-785.
ABSTRACT | FULL TEXT  

Relevance of Genetics and Genomics for Prevention and Treatment of Cardiovascular Disease: A Scientific Statement From the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group
Arnett et al.
Circulation 2007;115:2878-2901.
ABSTRACT | FULL TEXT  

Type 2 diabetes patients: profiles, treatment and daily practice
Zambon
Diabetes and Vascular Disease Research 2007;4:S12-S16.
 

The Role of Statins in Primary Prevention of Cardiovascular Disease
Eichler et al.
Arch Intern Med 2007;167:1100-1100.
FULL TEXT  

Statins: Targeting Inflammation by Lowering Low-Density Lipoprotein?
Tuzcu and Nicholls
J Am Coll Cardiol 2007;49:2010-2012.
FULL TEXT  

Low-Density Lipoprotein-Dependent and -Independent Effects of Cholesterol-Lowering Therapies on C-Reactive Protein: A Meta-Analysis
Kinlay
J Am Coll Cardiol 2007;49:2003-2009.
ABSTRACT | FULL TEXT  

Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? Yes
Grundy
BMJ 2007;334:982-982.
FULL TEXT  

Statins Reduce the Risk of Lung Cancer in Humans: A Large Case-Control Study of US Veterans
Khurana et al.
Chest 2007;131:1282-1288.
ABSTRACT | FULL TEXT  

Safety of Aggressive Lipid Management
Davidson and Robinson
J Am Coll Cardiol 2007;49:1753-1762.
ABSTRACT | FULL TEXT  

A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis
Patel et al.
Eur Heart J 2007;28:664-672.
ABSTRACT | FULL TEXT  

Inhibition of 3-Hydroxy-3-Methylglutaryl Coenzyme A (HMG CoA) Reductase Blunts Factor VIIa/Tissue Factor and Prothrombinase Activities via Effects on Membrane Phosphatidylserine
Dietzen et al.
Arterioscler. Thromb. Vasc. Bio. 2007;27:690-696.
ABSTRACT | FULL TEXT  

High-Density Lipoprotein Cholesterol: An Emerging Target for Stroke Treatment
Sanossian et al.
Stroke 2007;38:1104-1109.
ABSTRACT | FULL TEXT  

Does pravastatin promote cancer in elderly patients? A meta-analysis
Bonovas and Sitaras
CMAJ 2007;176:649-654.
ABSTRACT | FULL TEXT  

Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis
Nicholls et al.
JAMA 2007;297:499-508.
ABSTRACT | FULL TEXT  

The Use of Statins in Pediatrics: Knowledge Base, Limitations, and Future Directions
Belay et al.
Pediatrics 2007;119:370-380.
ABSTRACT | FULL TEXT  

The effect of intensive lipid lowering on coronary atheroma and clinical outcome
Houslay et al.
Heart 2007;93:149-151.
ABSTRACT | FULL TEXT  

Is it Time for a Cardiovascular Primary Prevention Trial in the Elderly?
Robinson et al.
Stroke 2007;38:441-450.
ABSTRACT | FULL TEXT  

Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive Protein: The PIOSTAT Study
Hanefeld et al.
J Am Coll Cardiol 2007;49:290-297.
ABSTRACT | FULL TEXT  

Statin Use and Risk of Colorectal Cancer
Coogan et al.
JNCI J Natl Cancer Inst 2007;99:32-40.
ABSTRACT | FULL TEXT  

Rational therapy of mixed dyslipidaemia in a patient with diabetes
Reasner
British Journal of Diabetes & Vascular Disease 2007;7:25-30.
ABSTRACT  

Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease
Shah
Eur Heart J 2007;28:5-12.
ABSTRACT | FULL TEXT  

Advances In The Prevention And Treatment Of Cardiovascular Disease
Weisfeldt and Zieman
Health Aff (Millwood) 2007;26:25-37.
ABSTRACT | FULL TEXT  

The Nitric Oxide-Donating Pravastatin Derivative, NCX 6550 [(1S-[1{alpha}(betaS*, {delta}S*), 2{alpha}, 6{alpha}, 8beta-(R*), 8a{alpha}]]-1,2,6,7,8,8a-Hexahydro-beta, {delta}, 6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-1-naphtalene-heptanoic Acid 4-(Nitrooxy)butyl Ester)], Reduces Splenocyte Adhesion and Reactive Oxygen Species Generation in Normal and Atherosclerotic Mice
Dever et al.
J. Pharmacol. Exp. Ther. 2007;320:419-426.
ABSTRACT | FULL TEXT  

The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part I: Pathophysiology and Clinical Trial Evidence (Risk Factors Through Stable Coronary Artery Disease)
Dzau et al.
Circulation 2006;114:2850-2870.
FULL TEXT